BRISTOL-MYERS SQUIBB COMPANY Gain (Loss) on Disposition of Other Assets
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Gain (Loss) on Disposition of Other Assets of $12.00 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-17.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfOtherAssets · last filed 2012-02-17
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on disposition of other assets for the quarter ending 2011-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on disposition of other assets for the quarter ending 2011-09-30 was $12.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on disposition of other assets for the quarter ending 2009-09-30 was $17.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on disposition of other assets for fiscal 2011 was $12.00M.
| Period end | Gain (Loss) on Disposition of Other Assets 3 month | Gain (Loss) on Disposition of Other Assets 6 month | Gain (Loss) on Disposition of Other Assets 9 month | Gain (Loss) on Disposition of Other Assets 12 month |
|---|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $12.00M derived: sum of 2 quarters · filed 2012-02-17 | $12.00M 10-K · filed 2012-02-17 | |
| 2011-09-30 | $12.00M 10-K · filed 2012-02-17 | $12.00M 10-Q · filed 2011-10-27 | ||
| 2009-09-30 | $17.00M 10-Q · filed 2010-10-26 | $72.00M 10-Q · filed 2010-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |